In the clinic, the PACIFIC trial provided the robust evidence of prolonged survival of locally advanced NSCLC after CRT followed by the PD-L1 inhibitor, durvalumab with acceptable toxicity. This evidence concerns the gene CD274 and non-small cell lung carcinoma.